Result card

  • CUR20: What is the reimbursement status of intravenous immunoglobulins (IVIG) across countries?
English

What is the reimbursement status of intravenous immunoglobulins (IVIG) across countries?

Authors: Antonio Migliore, Tapani Keranen, Sinikka Sihvo

Internal reviewers: Kristian Lampe

IVIG are reimbursed across countries for a list of approved indications. As IVIG are not formally used for Alzheimer’s disease including Mild Cognitive Impairment, no specific reimbursement schemes have been developed. Reimbursement of the IVIG therapy for off-label use cannot be excluded {Appendix CUR-3}.

Critical
Completely
Migliore A et al. Result Card CUR20 In: Migliore A et al. Health Problem and Current Use of the Technology In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 31 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267